Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of MXN 2.79 trillion. The enterprise value is 3.01 trillion.

Market Cap	2.79T
Enterprise Value	3.01T

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	Mar 13, 2026

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	88.87%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.21 and the forward PE ratio is 15.10.

PE Ratio	18.21
Forward PE	15.10
PS Ratio	5.26
PB Ratio	6.85
P/TBV Ratio	n/a
P/FCF Ratio	16.39
P/OCF Ratio	15.47
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.75, with an EV/FCF ratio of 17.71.

EV / Earnings	19.67
EV / Sales	5.89
EV / EBITDA	11.75
EV / EBIT	14.67
EV / FCF	17.71

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	6.05%
Revenue Per Employee	31.18M
Profits Per Employee	9.01M
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 23.15 billion in taxes.

Income Tax	23.15B
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +13.03% in the last 52 weeks. The beta is 0.40, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.40
52-Week Price Change	+13.03%
50-Day Moving Average	2,296.69
200-Day Moving Average	1,842.35
Relative Strength Index (RSI)	39.94
Average Volume (20 Days)	1,643

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.45

Income Statement

In the last 12 months, Gilead Sciences had revenue of MXN 530.07 billion and earned 153.21 billion in profits. Earnings per share was 122.06.

Revenue	530.07B
Gross Profit	417.91B
Operating Income	212.74B
Pretax Income	176.36B
Net Income	153.21B
EBITDA	262.43B
EBIT	212.74B
Earnings Per Share (EPS)	122.06

Balance Sheet

The company has 173.06 billion in cash and 459.82 billion in debt, giving a net cash position of -233.21 billion.

Cash & Cash Equivalents	173.06B
Total Debt	459.82B
Net Cash	-233.21B
Net Cash Per Share	n/a
Equity (Book Value)	407.20B
Book Value Per Share	329.34
Working Capital	117.54B

Cash Flow

In the last 12 months, operating cash flow was 180.37 billion and capital expenditures -10.14 billion, giving a free cash flow of 170.24 billion.

Operating Cash Flow	180.37B
Capital Expenditures	-10.14B
Depreciation & Amortization	47.99B
Net Borrowing	-31.09B
Free Cash Flow	170.24B
FCF Per Share	n/a

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 58.43, which amounts to a dividend yield of 2.62%.

Dividend Per Share	58.43
Dividend Yield	2.62%
Dividend Growth (YoY)	-3.93%
Years of Dividend Growth	2
Payout Ratio	47.04%
Buyback Yield	0.24%
Shareholder Yield	2.86%
Earnings Yield	5.49%
FCF Yield	6.10%

Dividend Details

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7